Marianna Rania, Anna Procopio, Paolo Zaffino, Elvira Anna Carbone, Teresa Vanessa Fiorentino, Francesco Andreozzi, Cristina Segura-Garcia, Carlo Cosentino, Franco Arturi
{"title":"Leveraging OGTT derived metabolic features to detect Binge-eating disorder in individuals with high weight: a \"seek out\" machine learning approach.","authors":"Marianna Rania, Anna Procopio, Paolo Zaffino, Elvira Anna Carbone, Teresa Vanessa Fiorentino, Francesco Andreozzi, Cristina Segura-Garcia, Carlo Cosentino, Franco Arturi","doi":"10.1038/s41398-025-03281-y","DOIUrl":null,"url":null,"abstract":"<p><p>Binge eating disorder (BED) carries a 6 times higher risk for obesity and accounts for roughly 30% of type 2 diabetes cases. Timely identification of early glycemic disturbances and comprehensive treatment can impact on the likelihood of associated metabolic complications and the overall outcome. In this study, machine learning techniques were applied to static and dynamic glucose-derived measures to detect BED among 281 individuals with high weight. Data from the classic (2 h) and the extended (5 h) glucose load were computed by multiple algorithms and two models with the most relevant features were trained to detect BED within the sample. The models were then tested on an independent cohort (N = 21). The model based on the 5 h-long glucose load exhibited the best performance (sensitivity = 0.75, specificity = 0.67, F score = 0.71) diagnosing BED in 7 out of 10 cases. Sex, HOMA-IR, HbA1c and plasma glucose in different times, and hypoglycemia events were the most sensitive features for BED diagnosis. This study is the first to use metabolic hallmarks to train ML algorithms for detecting BED in individuals at high risk for metabolic complications. ML techniques applied to objective and reliable glycemic features might prompt the identification of BED among individuals at high risk for metabolic complications, enabling timely and tailored multidisciplinary treatment.</p>","PeriodicalId":23278,"journal":{"name":"Translational Psychiatry","volume":"15 1","pages":"57"},"PeriodicalIF":5.8000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41398-025-03281-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Binge eating disorder (BED) carries a 6 times higher risk for obesity and accounts for roughly 30% of type 2 diabetes cases. Timely identification of early glycemic disturbances and comprehensive treatment can impact on the likelihood of associated metabolic complications and the overall outcome. In this study, machine learning techniques were applied to static and dynamic glucose-derived measures to detect BED among 281 individuals with high weight. Data from the classic (2 h) and the extended (5 h) glucose load were computed by multiple algorithms and two models with the most relevant features were trained to detect BED within the sample. The models were then tested on an independent cohort (N = 21). The model based on the 5 h-long glucose load exhibited the best performance (sensitivity = 0.75, specificity = 0.67, F score = 0.71) diagnosing BED in 7 out of 10 cases. Sex, HOMA-IR, HbA1c and plasma glucose in different times, and hypoglycemia events were the most sensitive features for BED diagnosis. This study is the first to use metabolic hallmarks to train ML algorithms for detecting BED in individuals at high risk for metabolic complications. ML techniques applied to objective and reliable glycemic features might prompt the identification of BED among individuals at high risk for metabolic complications, enabling timely and tailored multidisciplinary treatment.
期刊介绍:
Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod''s discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.